Surmodics, Inc. (SRDX) Receives Consensus Rating of “Hold” from Brokerages
Surmodics, Inc. (NASDAQ:SRDX) has been assigned an average recommendation of “Hold” from the six ratings firms that are presently covering the firm, Marketbeat Ratings reports. Four research analysts have rated the stock with a hold rating and two have issued a buy rating on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $40.00.
Several analysts have issued reports on the company. ValuEngine upgraded Surmodics from a “sell” rating to a “hold” rating in a research note on Friday, September 1st. BidaskClub upgraded Surmodics from a “sell” rating to a “hold” rating in a research report on Wednesday, August 23rd.
In other news, VP Joseph J. Stich sold 1,000 shares of the stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $27.28, for a total transaction of $27,280.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. 6.40% of the stock is currently owned by corporate insiders.
Shares of Surmodics (SRDX) opened at $29.15 on Tuesday. Surmodics has a one year low of $21.90 and a one year high of $32.80. The stock has a market capitalization of $398.01, a P/E ratio of 58.82 and a beta of 0.78.
Surmodics (NASDAQ:SRDX) last announced its quarterly earnings data on Wednesday, November 8th. The company reported $0.18 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.01) by $0.19. Surmodics had a return on equity of 6.18% and a net margin of 5.37%. The firm had revenue of $20.06 million for the quarter, compared to analysts’ expectations of $16.98 million. research analysts forecast that Surmodics will post -0.28 earnings per share for the current fiscal year.
Surmodics, Inc is a provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company operates through two segments: Medical Device and In Vitro Diagnostics. The Company’s Medical Device segment consists of surface modification coating technologies to improve access, deliverability and predictable deployment of medical devices; international cardiology and peripheral balloon design, development and manufacturing, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device.
Receive News & Ratings for Surmodics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Surmodics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.